GlassScriptPhysician profile
Maria A Moogerfeld
NPI 1750439436
$1,011.65
in general payments reported to CMS, 2019-2025
25 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.61 · 2021: $266 · 2022: $138 · 2023: $198 · 2024: $234 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $567.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $262.03 | 2021-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $91.53 | 2023-2024 | Jardiance, Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $64.31 | 2022-2025 | |
| Abbott Laboratories | $59.94 | 2021-2023 | Freestyle Libre |
| Xeris Pharmaceuticals, INC. | $58.46 | 2021-2023 | Gvoke Hypopen |
| Novo Nordisk INC | $55.45 | 2023-2025 | Wegovy |
| Pfizer INC. | $52.96 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $41.66 | 2019-2025 | Airsupra |
| Kowa Pharmaceuticals America, INC. | $27.38 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.33 | 2019 | |
| Janssen Pharmaceuticals, INC | $26.00 | 2021 | |
| Merck Sharp & Dohme LLC | $23.53 | 2021 | |
| Sunovion Pharmaceuticals INC. | $22.99 | 2021 | |
| Abbvie INC. | $20.82 | 2024 | |
| Sanofi Pasteur INC. | $20.37 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $20.11 | 2021 | |
| Nevro Corp. | $18.88 | 2023 | Senza |
| Exact Sciences Corporation | $17.23 | 2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $16.20 | 2024 | Shingrix |
| Ibsa Pharma INC. | $15.60 | 2023 | Tirosint, Licart |
| E.R. Squibb & Sons, L.L.C. | $14.61 | 2024 | Eliquis |
| Phathom Pharmaceuticals, INC. | $13.83 | 2024 | Voquezna |
| Esperion Therapeutics, INC. | $13.80 | 2024 | Nexletol |
| Baxter Healthcare | $13.56 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Bayer Healthcare Pharmaceuticals INC. | $13.07 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Moogerfeld listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.